

NATIONAL QUALITY FORUM

Neurology Endorsement Maintenance Phase 1
Workgroup 4 Conference Call
Ischemic Stroke Treatment Measures
June 7, 2012
2:00-4:00 pm ET

Please use the following information to access the conference call line and webinar:

Dial-In Number: (855) 226-0348

Conference ID: 78558154

Webinar link: <http://www.MyEventPartner.com/QualityForum295>

PUBLIC AGENDA

- 2:00 pm** **Welcome and Introductions**
Karen Johnson, MS, Neurology Project Senior Director
Suzanne Theberge, MPH, Neurology Project Manager
- 2:15 pm** **Measure Discussion**
- 1952: Time to Intravenous Thrombolytic Therapy (American Heart Association)
 - 0437: STK 04: Thrombolytic Therapy (The Joint Commission)
 - 0242: Tissue Plasminogen Activator (t-PA) Considered (AMA-PCPI)
 - 2022: Tissue Plasminogen Activator (t-PA) Initiated (AMA-PCPI)
 - 0438: STK 05: Antithrombotic Therapy By End of Hospital Day Two (The Joint Commission)
 - 0435: STK 02: Discharged on Antithrombotic Therapy (The Joint Commission)
 - 0325: Discharged on Antithrombotic Therapy (AMA-PCPI)
 - 0439: STK-06: Discharged on Statin Medication (The Joint Commission)
- 3:50 pm** **Public & Member Comment**
- 3:55 pm** **Next Steps**
Ms. Theberge
- 4:00 pm** **Adjourn**